BR112015000321A2 - formulações de laquinimod sem agente alcalinizante - Google Patents

formulações de laquinimod sem agente alcalinizante

Info

Publication number
BR112015000321A2
BR112015000321A2 BR112015000321A BR112015000321A BR112015000321A2 BR 112015000321 A2 BR112015000321 A2 BR 112015000321A2 BR 112015000321 A BR112015000321 A BR 112015000321A BR 112015000321 A BR112015000321 A BR 112015000321A BR 112015000321 A2 BR112015000321 A2 BR 112015000321A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
individual
alkalizing agent
stable pharmaceutical
provides
Prior art date
Application number
BR112015000321A
Other languages
English (en)
Portuguese (pt)
Inventor
Licht Danit
Sarfati Gadi
Lovinger Ioana
Safadi Muhammad
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112015000321A2 publication Critical patent/BR112015000321A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015000321A 2012-07-11 2013-07-10 formulações de laquinimod sem agente alcalinizante BR112015000321A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670268P 2012-07-11 2012-07-11
PCT/US2013/049894 WO2014011750A1 (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Publications (1)

Publication Number Publication Date
BR112015000321A2 true BR112015000321A2 (pt) 2017-06-27

Family

ID=49914501

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000321A BR112015000321A2 (pt) 2012-07-11 2013-07-10 formulações de laquinimod sem agente alcalinizante

Country Status (19)

Country Link
US (1) US20140018386A1 (enExample)
EP (1) EP2872141A4 (enExample)
JP (1) JP2015527321A (enExample)
KR (1) KR20150036553A (enExample)
CN (1) CN104470519A (enExample)
AR (1) AR091706A1 (enExample)
AU (1) AU2013290274A1 (enExample)
BR (1) BR112015000321A2 (enExample)
CA (1) CA2873230A1 (enExample)
EA (1) EA201590193A1 (enExample)
HK (1) HK1209054A1 (enExample)
IL (1) IL236229A0 (enExample)
MX (1) MX2015000398A (enExample)
NZ (1) NZ630241A (enExample)
SG (2) SG11201407688QA (enExample)
TW (1) TW201408299A (enExample)
UA (1) UA115555C2 (enExample)
WO (1) WO2014011750A1 (enExample)
ZA (1) ZA201500287B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN107823150A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种可快速分散的片剂及其制备方法
CN107823168A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种快速溶解的片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
EP2687512A1 (en) * 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
US7989473B2 (en) * 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
EP2234485B1 (en) * 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
SG10201606204TA (en) * 2011-07-28 2016-09-29 Teva Pharma Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta

Also Published As

Publication number Publication date
JP2015527321A (ja) 2015-09-17
AR091706A1 (es) 2015-02-25
IL236229A0 (en) 2015-01-29
SG11201407688QA (en) 2014-12-30
ZA201500287B (en) 2016-10-26
CN104470519A (zh) 2015-03-25
US20140018386A1 (en) 2014-01-16
KR20150036553A (ko) 2015-04-07
AU2013290274A1 (en) 2014-11-27
EP2872141A1 (en) 2015-05-20
MX2015000398A (es) 2015-04-10
EP2872141A4 (en) 2016-01-13
WO2014011750A1 (en) 2014-01-16
WO2014011750A8 (en) 2014-12-04
EA201590193A1 (ru) 2015-04-30
SG10201700198VA (en) 2017-02-27
UA115555C2 (uk) 2017-11-27
HK1209054A1 (zh) 2016-03-24
NZ630241A (en) 2017-09-29
TW201408299A (zh) 2014-03-01
CA2873230A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
IN2015DN00376A (enExample)
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112015023409A2 (pt) composições farmacêuticas
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112015026053A2 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112015012497A2 (pt) combinações farmacêuticas
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
BR112014030777A2 (pt) método e composição para aliviar sintomas de tumor
BR112015029709A2 (pt) dihidroetorfina para o fornecimento de alívio da dor e anestesia
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
BR112018007399A2 (pt) composição, método de tratamento, kit de partes e forma de dosagem

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]